Shares of Novanta jumped 7.6% in pre-market trading to $173.94, closing a gap that had persisted since analysts raised their fair value estimate from $171.50 to $175 following first-quarter results. The rally puts the stock within pennies of that new target, forcing investors to decide whether the good news is already priced in — or whether a transformational acquisition could power the next leg higher.
• A 37% Bookings Surge Signals Customers Are Placing Bigger Bets
Bookings grew 37% year-over-year in Q1, with a book-to-bill ratio of 1.10, and all business units achieved double-digit bookings and revenue growth.
Revenue rose 10.4% to $257.7 million, with 3.1% organic growth. That matters because a book-to-bill above 1.0 means orders are outpacing shipments, building a backlog that supports future quarters. New product sales grew over 50% year-over-year, raising the share of revenue from recent innovations to 27% of sales. For shareholders, that pipeline depth reduces the risk that growth stalls once current orders ship.
• Tariffs Squeezed Margins Before Management Could Adjust Prices
Adjusted gross margin declined 60 basis points because higher freight, tariff, and material costs shifted faster than Novanta could surcharge customers.
Tariff rates on categories like aluminum jumped from 25% to 50% within four weeks. Despite that, adjusted EBITDA rose 14.2% to $57.1 million, expanding the margin by 70 basis points — meaning the company offset cost pressure elsewhere. Investors should watch whether repricing catches up in Q2, where guidance calls for revenue of $259–$264 million and adjusted EBITDA of $58–$62 million.
• A $1.45 Billion Acquisition Reshapes the Revenue Mix
Novanta agreed to acquire Riverpoint Medical for up to $1.45 billion — $1.2 billion upfront plus a potential $250 million milestone payment — to push deeper into disposable surgical products. Riverpoint is expected to grow revenue 12%–15% annually, roughly double Novanta's rate, and would double recurring medical consumables revenue to approximately $300 million. The deal, expected to close this quarter, lifts net leverage to about 2.7× after closing , raising execution risk if integration falters.
• The Valuation Leaves Little Room for Error
Novanta's trailing price-to-earnings ratio sits at roughly 105×, well above the U.S. electronics industry average of 31× and its peer average of 56×.
The revised fair value model applies a forward earnings multiple of about 34.7× , banking on full-year 2026 revenue of $1.04–$1.055 billion. At $174, the stock is priced for near-flawless execution on both organic growth and a billion-dollar integration — a narrow margin of safety if macro headwinds intensify.